View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 31, 2011

FDA approves Stealth Therapeutics implantable arm port

The US Food and Drug Administration (FDA) has granted approval for Stealth Therapeutics' Invisiport implantable arm port, intended for use in patients requiring long-term intravenous treatment.

The US Food and Drug Administration (FDA) has granted approval for Stealth Therapeutics’ Invisiport implantable arm port, intended for use in patients requiring long-term intravenous treatment.

The Invisiport incorporates a patented self-deploying wing that reduces insertion size and improves stability after implantation.

The port provides a less invasive, patient-friendly option to standard chest ports and peripherally inserted central catheters.

Kegonsa Seed Fund and Wisconsin’s premier seed venture capital fund has supported Stealth in FDA submission and commercialisation work.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management